JPMorgan analyst Anupam Rama lowered the firm’s price target on Ideaya Biosciences to $66 from $69 and keeps an Overweight rating on the shares. The analyst updated models in the SMid-cap biotechnology space.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Ideaya Biosciences price target lowered to $53 from $60 at Oppenheimer
- Ideaya Biosciences reports Q2 EPS (68c), consensus (53c)
- IDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
- Ideaya Biosciences enters option, license agreement for B7H3/PTK7 BsADC program
- Ideaya Biosciences price target raised to $69 from $65 at JPMorgan